

**CONTACT - Media:**

Amsterdam +31.20.721.4488  
Lisbon +351 210 600 614

Brussels +32.2.620.15.50  
Paris +33.1.70.48.24.45

**CONTACT - Investor Relations:**

+33.1.70.48.24.17

## ASIT BIOTECH MAKES DEBUT ON EURONEXT BRUSSELS AND PARIS

**Biopharmaceutical company specialized in allergies valued at € 89.3 million**



**Brussels, Paris – 11 May 2016** – Euronext today celebrated the listing of ASIT biotech on its Brussels and Paris markets. ASIT biotech joins a community of 77 life sciences issuers listed on Euronext.

Headquartered in Belgium, ASIT biotech s.a. (formerly known as Biotech Tools) is a clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+™ technology platform. The company was founded in 1997 as a spin-off company of the Université libre de Bruxelles.

ASIT biotech (ticker code: ASIT) raised € 23.5 million in new capital at a final offer price of € 7.00 per share. With a total of 12,756,800 shares admitted on the day of listing, the company has an initial market capitalisation of € 89.3 million.

The proceeds of the IPO will help ASIT biotech to support the preclinical and clinical development of product candidates, to cover general corporate purposes and to accelerate the discovery of new ASIT+™ platform-based product candidates.

Thierry Legon, Chief Executive Officer of ASIT biotech, declared: *“After the successful closing of the subscription period, today’s listing marks a further major milestone in ASIT biotech’s development and ambition to change the face of the current allergy immunotherapy (AIT) market by overcoming the main drawbacks of the existing AIT treatments. This initial public offering will support the strong momentum established by our achievements and will allow us to bring our gp-ASIT+™ lead product candidate for grass pollen allergy through Phase III, currently underway in Europe, and to move towards a first application for commercialisation in Germany. The management team and the Board of Directors would like to take this opportunity to thank both private and institutional investors for subscribing in the offer. It indicates a strong confidence in and support for our strategy.”*



#### CONTACTS -

Pauline Bucaille(Europe):	+33 1 70 48 24 41; <a href="mailto:pbucaille@euronext.com">pbucaille@euronext.com</a>
Alice Jentink (Amsterdam):	+31 20 721 4488; <a href="mailto:ajentink@euronext.com">ajentink@euronext.com</a>
Pascal Brabant (Brussels):	+32 2 620 15 50; <a href="mailto:pbrabant@euronext.com">pbrabant@euronext.com</a>
Sandra Machado (Lisbon):	+351 210 600 614; <a href="mailto:smachado@euronext.com">smachado@euronext.com</a>
Aichata Tandjigora (Paris):	+33 1 70 48 24 43; <a href="mailto:atandjigora@euronext.com">atandjigora@euronext.com</a>

#### About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies. ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

#### About EnterNext

Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalisations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs. EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level.

#### About Euronext

Euronext is the primary exchange in the Euro zone with more than 1 300 listed issuers worth more than €3.0 trillion in market capitalization as of end December 2015, an unmatched blue chip franchise consisting of 25 issuers in the EURO STOXX 50® benchmark and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs' access to capital markets.

#### Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided "as is" without representation or warranty of any kind. Whilst all reasonable care has been taken to ensure the

accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at <https://www.euronext.com/terms-use>.

© 2016, Euronext N.V. - All rights reserved.